Financial reports
10-K
2023 FY
Annual report
1 Apr 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
30 Mar 23
10-K
2022 FY
Annual report
22 Mar 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
10-K
2021 FY
Annual report
28 Feb 22
Current reports
8-K/A
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
1 Apr 24
8-K
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
1 Apr 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
18 Mar 24
8-K
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors
12 Mar 24
8-K
Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
13 Nov 23
8-K
Departure of Directors or Certain Officers
9 Nov 23
8-K
Departure of Directors or Certain Officers
6 Oct 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
28 Sep 23
8-K
Other Events
30 Aug 23
8-K
Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
14 Aug 23
Registration and prospectus
S-3
Shelf registration
21 Apr 21
S-8
Registration of securities for employees
31 Mar 21
424B5
Prospectus supplement for primary offering
23 Mar 21
S-3MEF
Registration of additional securities for an S-3
22 Mar 21
424B2
Prospectus for primary offering
4 Feb 21
S-3
Shelf registration
22 Jan 21
424B3
Prospectus supplement
8 Jan 21
424B5
Prospectus supplement for primary offering
21 Dec 20
424B3
Prospectus supplement
11 Dec 20
S-1/A
IPO registration (amended)
1 Dec 20
Proxies
DEFA14A
Additional proxy soliciting materials
26 Apr 23
DEF 14A
Definitive proxy
30 Mar 23
DEF 14A
Definitive proxy
11 Apr 22
PRE 14A
Preliminary proxy
1 Apr 22
DEFA14A
Additional proxy soliciting materials
14 Sep 21
DEF 14A
Definitive proxy
9 Aug 21
PRE 14A
Preliminary proxy
29 Jul 21
DEFA14A
Additional proxy soliciting materials
11 May 21
DEF 14A
Definitive proxy
15 Apr 21
PRE 14A
Preliminary proxy
5 Apr 21
Other
EFFECT
Notice of effectiveness
30 Apr 21
CORRESP
Correspondence with SEC
27 Apr 21
UPLOAD
Letter from SEC
26 Apr 21
EFFECT
Notice of effectiveness
1 Feb 21
CORRESP
Correspondence with SEC
28 Jan 21
UPLOAD
Letter from SEC
28 Jan 21
EFFECT
Notice of effectiveness
9 Dec 20
CORRESP
Correspondence with SEC
7 Dec 20
CORRESP
Correspondence with SEC
7 Dec 20
UPLOAD
Letter from SEC
27 Nov 20